[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2]XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:Profiles,trends,and determinants[J].Chin Med J(Engl),2022,135(5):584-590.
[3]LI X,XU J,XIE J,et al.Research progress in targeted therapy and immunotherapy for gastric cancer[J].Chin Med J(Engl),2022,135(11):1299-1313.
[4]KOBAYASHI A.Roles of NRF3 in the Hallmarks of cancer:Proteasomal inactivation of tumor suppressors[J].Cancers(Basel),2020,12(9):2681.
[5]CHEVILLARD G,BLANK V.NFE2L3(NRF3):The cinderella of the cap 'n' collar transcription factors[J].Cell Mol Life Sci,2011,68(20):3337-3348.
[6]NOUHI Z,CHEVILLARD G,DERJUGA A,et al.Endoplasmic reticulum association and N-linked glycosylation of the human Nrf3 transcription factor[J].FEBS Lett,2007,581(28):5401-5406.
[7]CAI BQ,CHEN WM,ZHAO J,et al.Nrf3 promotes 5-FU resistance in colorectal cancer cells via the NF-kappaB/BCL-2 signaling pathway in vitro and in vivo[J].J Oncol,2021,2021:9355555.
[8]CHOWDHURY A,KATOH H,HATANAKA A,et al.Multiple regulatory mechanisms of the biological function of NRF3(NFE2L3) control cancer cell proliferation[J].Sci Rep,2017,7(1):12494.
[9]KOBAYASHI A,WAKU T.New addiction to the NRF2-related factor NRF3 in cancer cells:Ubiquitin-independent proteolysis through the 20S proteasome[J].Cancer Sci,2020,111(1):6-14.
[10]BURY M,LE CALVE B,LESSARD F,et al.NFE2L3 controls colon cancer cell growth through regulation of DUX4,a CDK1 inhibitor[J].Cell Rep,2019,29(6):1469-1481 e9.
[11]AONO S,HATANAKA A,HATANAKA A,et al.β-Catenin/TCF4 complex-mediated induction of the NRF3(NFE2L3) gene in cancer cells[J].Int J Mol Sci,2019,20(13):3344.
[12]QIAN J,HUANG C,ZHU Z,et al.NFE2L3 promotes tumor progression and predicts a poor prognosis of bladder cancer[J].Carcinogenesis,2022,43(5):457-468.
[13]WANG C,SAJI M,JUSTINIANO SE,et al.RCAN1-4 is a thyroid cancer growth and metastasis suppressor[J].JCI Insight,2017,2(5):e90651.
[14]WANG H,ZHAN M,YANG R,et al.Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients[J].Cell Cycle,2018,17(17):2164-2174.
[15]HANAHAN D.Hallmarks of cancer:New dimensions[J].Cancer Discov,2022,12(1):31-46.
[16]ECKER J,LIEBISCH G.Application of stable isotopes to investigate the metabolism of fatty acids,glycerophospholipid and sphingolipid species[J].Prog Lipid Res,2014,54:14-31.
[17]TROUSIL S,LEE P,PINATO DJ,et al.Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway[J].Cancer Res,2014,74(23):6867-6877.
[18]来嘉伟,程永毅,周建成.代谢组学和肾癌中代谢重编程的研究进展[J].现代肿瘤医学,2022,30(17):3217-3220.
LAI JW,CHENG YY,ZHOU JC.Progress in metabonomics and metabolic reprogramming in renal cell carcinoma[J].Modern Oncology,2022,30(17):3217-3220.
[19]KELLER M,ROHLF K,GLOTZBACH A,et al.Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth[J].J Exp Clin Cancer Res,2023,42(1):25.
[20]MARCHAN R,LESJAK MS,STEWART JD,et al.Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities[J].Cell Cycle,2012,11(24):4499-4506.
[21]GADIYA M,MORI N,CAO MD,et al.Phospholipase D1 and choline kinase-alpha are interactive targets in breast cancer[J].Cancer Biol Ther,2014,15(5):593-601.
[22]STEWART JD,MARCHAN R,LESJAK MS,et al.Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis[J].Proc Natl Acad Sci USA,2012,109(21):8155-8160.
[23]LESJAK MS,MARCHAN R,STEWART JD,et al.EDI3 links choline metabolism to integrin expression,cell adhesion and spreading[J].Cell Adh Migr,2014,8(5):499-508.